# Evaluate Use of Mangosteen Juice Added to Usual Care in Reducing Risk of Recurrent Atrial Fibrillation

> **NCT00951301** · PHASE1 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 143 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** mangosteen juice
- **DRUG:** placebo juice

## Key facts

- **NCT ID:** NCT00951301
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-07
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 143 (ACTUAL)
- **Why stopped:** Significantly lower accrual rate than anticipated, time constraints.
- **Last updated:** 2016-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00951301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00951301, "Evaluate Use of Mangosteen Juice Added to Usual Care in Reducing Risk of Recurrent Atrial Fibrillation". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00951301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*